Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $11.3752W HIGH $27.24
Volume
78.85 K
Value Traded
2.19 M
Short % Float
3.93%
Days to Cover
2.5
+0.72%Week
-24.45%1 Month
-6.25%3 Month
+2.67%6 Month
-96.51%5 Year
-47.72%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
343.45 M
EPS (TTM)
4.45
P/E Ratio
3.93
Ent. Value
238.56 M
Total Shares
19.51 M
Float Shares
13.10 M
Insiders
22.64%
Institutions
7.12%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
PRE Catalyst Timeline
Dated clinical, regulatory and corporate events for Prenetics Global Limited
Past FDA Catalysts and PDUFA Decisions
How PRE actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Prenetics Global Limited is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every PRE program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Leogrande Hudson BlakeDirector | Option | 2,000 8,001 held | $0.00 | 10/04/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PRE
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in PRE for Q2 2026. | ||||
PRE Institutional Ownership Trends
PRE Short Interest
Shares sold short, counted twice a month.
3.93%
Short % of Float
of tradable shares sold short
515.0K
Shares Sold Short
+16.5% vs prior count
2.5 Moderate
Days to Cover
trading days of normal volume to buy every short share back
204.2K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PRE ranks across every disease it competes in
Competitive Position is a premium feature
See how PRE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPRE News
PREPrenetics to Report Q2 2026 Financial Results on August 18, 2026, Live-Stream Earnings Event on Stocktwits, and Announces Upcoming Conference Participation
Prenetics Global Limited will release its Q2 2026 financial results on August 18, 2026, before market open. The company is shifting to a detailed shareholder letter format for reporting, along with a live-streamed earnings event on Stocktwits. Additionally, Prenetics will participate in several upcoming investor conferences, showcasing its growth and strategy.
Read more →PRE▼ -8%on this news
Prenetics Announces Record Q1 2026 Results with IM8 Revenue Reaching a Record $16.7 Million in May, Implying $200 Million in Annualized Recurring Revenue
Prenetics has announced its financial results for Q1 2026, reporting a revenue of $36.0 million, which includes $33.8 million from its IM8 health brand. This marks a significant 23.1% increase in IM8 revenue compared to the previous quarter and represents nearly six times year-over-year growth. The company has raised its full-year revenue guidance for IM8, now expecting $190 million to $210 million, driven by strong consumer demand and continuous product expansion. Despite a loss of $23.1 million due to non-cash items, Prenetics remains optimistic about future growth as it improves gross margins and expands internationally.
Read more →PREPrenetics Appoints Hudson Leogrande, Founder and CEO of Multi-Billion-Dollar DTC Brand Comfrt, to Board of Directors as IM8 Accelerates TikTok and Meta Expansion
Prenetics has appointed Hudson Leogrande, the CEO of Comfrt, to its Board of Directors as an independent director. This appointment aims to enhance corporate governance as the company aims for significant growth in its IM8 brand. IM8 has seen a rapid increase in annual recurring revenue, projected to reach between $250 million and $300 million by the end of 2026. Leogrande's expertise in direct-to-consumer commerce is anticipated to drive further expansion and efficiency in IM8's marketing strategies through social media platforms.
Read more →PRE▲ +5.9%on this news· ran to +22% by day 3
Prenetics Announces Jay Shetty as IM8 Global Ambassador and Shareholder in Multi-Year Partnership
Prenetics Global Limited has announced a multi-year partnership with Jay Shetty, who will serve as the Global Ambassador and shareholder for its IM8 health brand. This partnership marks IM8's first ambassador from outside the sports arena and aims to expand its presence in the wellness market. Shetty has been using IM8's Daily Ultimate Essentials product for nearly a year and has a significant social media following that can help promote health and longevity initiatives worldwide. IM8 expects to achieve revenue between $190 million and $210 million for the year 2026 following impressive growth figures reported in Q1 2026.
Read more →PREPrenetics Announces Preliminary Record Q1 2026 Results with IM8 Revenue Growing Nearly 6x YoY; Company Raises Full-Year 2026 IM8 Revenue Guidance to $190M–$210M
Prenetics Global Limited (NASDAQ: PRE) reported preliminary Q1 2026 results, showcasing a significant revenue increase driven by its IM8 brand, which grew nearly 6x year-over-year. The company raised its full-year IM8 revenue guidance to between $190 million and $210 million. Despite a reported operational loss, the company anticipates continued growth with new product launches and strong international expansion.
Read more →PREPrenetics Welcomes Brian J. Rosin as Chief Financial Officer of IM8
Prenetics Global Limited (NASDAQ: PRE) has appointed Brian J. Rosin as the Chief Financial Officer of IM8, aiming to support its rapid expansion. Rosin, a seasoned leader in consumer health and e-commerce finance, is tasked with steering the company's financial strategies as IM8 grows. Currently, IM8 is one of the fastest-growing supplement brands, reported to reach revenues between $190 million to $210 million in 2026. The successful launch and sales in over 40 countries highlight IM8's emerging status in the global health market.
Read more →PREPrenetics to Report Q1 2026 Financial Results on May 14, 2026 and Host Earnings Conference Call
Prenetics Global Limited will announce its Q1 2026 financial results on May 14, 2026, before market open. The earnings conference call will take place at 8:30 a.m. ET, featuring a Q&A session with analysts. The company highlights its successful IM8 brand, which has quickly gained traction in the consumer health market.
Read more →PREPrenetics’ IM8 Named Exclusive Health Supplements Partner of Inter Miami CF in Multi-Year Partnership
Prenetics Global Limited (NASDAQ: PRE) announced a multi-year partnership with Inter Miami CF, making IM8 the club's exclusive Official Health Supplements Partner. This agreement includes an equity stake in Prenetics, marking a notable first for Inter Miami CF in terms of brand partnerships. IM8 will integrate its health supplements into the routines of Inter Miami players, while also gaining marketing rights and global branding opportunities. The partnership aims to enhance IM8's presence in professional sports and leverage Inter Miami's global fanbase for future growth.
Read more →PREPrenetics’ IM8 Health Partners with Vitamin Angels to Combat Global Malnutrition, Commits to Impacting 400,000 Mothers and Children in Year One
Prenetics Global Limited has announced a partnership with Vitamin Angels to tackle malnutrition among vulnerable populations. The collaboration aims to provide essential nutrition to 400,000 pregnant women, infants, and young children in its first year. Vitamin Angels brings extensive experience and infrastructure, having supported over 74 million women and children annually. The partnership represents an extension of IM8’s mission to make quality nutrition accessible, highlighting a commitment to improving global health outcomes.
Read more →PREPrenetics Announces NBA Champion and Two-Time MVP Giannis Antetokounmpo as IM8 Global Partner and Shareholder in Multi-Year Partnership
Prenetics Global Limited has announced a multi-year partnership with NBA Champion Giannis Antetokounmpo, who becomes the first NBA athlete shareholder in a NASDAQ-listed health brand. This collaboration aims to leverage Giannis's extensive social media reach and align with IM8's growth strategy, which has seen rapid revenue growth since its launch. The partnership is expected to enhance IM8's market presence and credibility across various sports.
Read more →PREPrenetics' IM8 Partners with Superpower to Personalize the Future of Supplementation
Prenetics' IM8 has partnered with Superpower to create a unique system that combines clinical-grade supplementation with comprehensive blood testing. This partnership allows consumers to measure the efficacy of their supplements through a closed-loop system. IM8 subscribers can access Superpower's blood testing services at a significantly reduced price, promoting a proactive approach to health management.
Read more →PREPrenetics to Participate in the 38th Annual ROTH Conference
Prenetics Global Limited (PRE) announced its participation in the upcoming 38th Annual ROTH Conference scheduled from March 22 to March 24, 2026. Key executives, including CEO Danny Yeung, will conduct one-on-one meetings and participate in discussions available via webcast. The company's IM8 brand has achieved significant success, surpassing $100 million in revenue within just 11 months of its launch. IM8 is now available in over 30 countries, emphasizing Prenetics' commitment to advancing consumer health through science-based products.
Read more →PRE▲ +18.1%on this news· ran to +36% by day 3
Prenetics Authorizes $40 Million Share Repurchase Program
Prenetics Global Limited (NASDAQ: PRE) has announced a $40 million share repurchase program, reflecting confidence in its current stock value. The management team has collectively invested approximately $2.75 million in company shares, underlining their commitment. With $164 million in total adjusted liquidity and a zero-debt status, Prenetics is well-positioned to fund growth, particularly in their IM8 brand, which aims for substantial revenue increase in 2026. The repurchase program highlights the board's belief that current share prices do not fully reflect the company's underlying value.
Read more →PREPrenetics Executives Execute Second Consecutive Round of Post-Earnings Open Market Share Purchases of $1.3 Million— Cumulative Personal Investment Across Both Rounds Reaches $2.7 Million
Prenetics Global Limited's executives have made a second consecutive round of open market purchases, investing approximately $1.3 million in shares. This follows a prior investment of about $1.45 million, bringing total personal investments to $2.75 million. CEO Danny Yeung emphasized the strong performance of the IM8 brand and the belief that the share price does not reflect the company's progress.
Read more →PRE▼ -8.4%on this news
Prenetics Launches IM8 Daily Ultimate Essentials PRO — A Clinical Formula with Two New Flavours
Prenetics Global Limited has launched Daily Ultimate Essentials PRO, a new clinical-grade health supplement featuring enhanced potency and bioavailability. The reformulated product introduces two new flavors, Mango + Passionfruit and Lemon + Orange, while keeping the price unchanged for all customers. The PRO formula incorporates advanced nutritional science, including bioactive vitamin forms for superior absorption.
Read more →PRE▼ -7.7%on this news· ran to -28% by day 3shared move
Prenetics Reports Record Q4 and FY 2025 Results: IM8 Achieves $120M ARR¹ in 12 Months, Revenue Surges 480% YoY
Prenetics Global Limited reported record financial results for Q4 and FY 2025, driven by the success of its IM8 brand, which achieved $120 million in annual recurring revenue within just 12 months. The company's revenue surged by 480% year-over-year to $92.4 million. Strategic divestitures have improved liquidity, positioning Prenetics for continued growth, despite facing challenges such as increased costs and ongoing losses.
Read more →PRE▼ -7.7%on this news· ran to -28% by day 3shared move
Prenetics Completes $70 Million Insighta Sale to Tencent, Bolstering Balance Sheet to $171.1 Million in Total Adjusted Liquidity Final Milestone in Strategic Transformation Positions Company to Accelerate IM8 Global Expansion with Zero Debt
Prenetics Global Limited has successfully completed the sale of its 35% equity stake in Insighta to Tencent for $70 million. This transaction significantly boosts Prenetics' cash resources, resulting in a total adjusted liquidity of $171.1 million, while maintaining zero debt. The company aims to leverage this capital to expedite the global expansion of its IM8 health brand. Financial updates will be presented during their upcoming earnings announcement on February 18, 2026.
Read more →PREPrenetics Completes $70 Million Insighta Sale to Tencent, Bolstering Balance Sheet to $171.1 Million in Total Adjusted Liquidity
Prenetics Global Limited has completed the sale of its 35% equity interest in Insighta to Tencent for $70 million. This transaction significantly boosts the company's liquidity, bringing total adjusted liquidity to $171.1 million. With zero debt, Prenetics aims to accelerate the global expansion of its IM8 brand, which has shown rapid growth in the consumer health sector.
Read more →PREPrenetics Appoints Renowned Longevity Expert and Health-Tech CEO, Dr. Darshan Shah, to Board of Directors Appointment Strengthens Board with Deep Clinical and Commercial Expertise in Healthspan Optimization, Aligning with IM8 Growth Strategy
Prenetics Global Limited has appointed Dr. Darshan Shah, a noted expert in longevity medicine, to its Board of Directors, effective February 16, 2026. His extensive experience, including 20,000+ surgeries and leadership of the health optimization brand, Next Health, brings valuable insights to Prenetics’ strategy. Dr. Shah's involvement is expected to bolster both the scientific and commercial capabilities of the company, particularly in advancing its IM8 brand in health and longevity. This strategic move aligns with Prenetics' goals of scaling its offerings and enhancing shareholder value.
Read more →PREPrenetics Appoints Renowned Longevity Expert and Health-Tech CEO, Dr. Darshan Shah, to Board of Directors
Prenetics Global Limited has appointed Dr. Darshan Shah, a prominent expert in longevity medicine, to its Board of Directors as an independent director. Dr. Shah, who has extensive clinical and entrepreneurial experience, is expected to significantly enhance the Board's expertise and contribute to the company's growth strategy, particularly with its IM8 health brand. His background includes over 20,000 surgeries and a successful history of scaling health optimization services, which aligns with Prenetics' commitment to innovate and expand in the health sciences sector.
Read more →About Prenetics Global Limited
BIOPHARMAWATCH ELITE PLUS
Trade the next PRE catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime